# Emedgene Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emedgene-technologies

- Industry: Software
- Headquarters: Palo Alto, US
- Website: www.emedgene.com
- Total disclosed funding: $6M
- Latest round: Series A (Feb 19, 2019)
- Investors on record: 4

## About

Emedgene Technologies Ltd. develops advanced software solutions that enhance germline variant interpretation for genomic research and rare disease analysis, leveraging AI and automation to optimize workflows and reporting.Emedgene Technologies Ltd. provides software solutions for genetic variant interpretation. The company was co-founded by Einat Metzer and Niv Mizrahi, with Einat Metzer serving as the CEO. Headquartered in Palo Alto, US, Emedgene raised USD 6.00 mn in a Series A funding round led by OTV on February 19, 2019, bringing the total amount raised to USD 6.00 mn. The company has completed three investment deals to date.Emedgene specializes in advanced software solutions for germline variant interpretation, focusing on streamlining tertiary analysis workflows for rare diseases and genetic research applications. Their flagship product, Emedgene variant interpretation software, utilizes explainable AI (XAI) and automation to improve user-defined variant interpretation, prioritization, curation, and research report generation. It integrates seamlessly with existing laboratory workflows, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES), enabling analysis of various variant types, including single nucleotide variants (SNVs), insertions and deletions (indels), and copy number variants (CNVs). Emedgene serves a diverse clientele, including clinical genetic laboratories, research institutions, and healthcare providers across North America, Europe, and Asia, supporting their insights into hereditary diseases and genetic conditions.Emedgene's revenue model is subscription-based, where clients pay for access to the platform based on data volume and functionalities required. The company engages in direct B2B transactions with clinical laboratories and research facilities utilizing its software for genomic data analysis. Revenue is generated through annual subscription contracts that may include onboarding services, training, and ongoing technical support. The pricing structure accommodates different client needs, with options tailored for institutions conducting routine genetic testing and those involved in extensive research projects. Emedgene's solutions enhance operational efficiency for clients, allowing them to adapt to the changing landscape of genomic medicine.Emedgene is focused on developing new software products to enhance its service offerings. The company plans to expand into additional markets in Europe and Asia by the end of 2023. The recent Series A funding of USD 6 mn will support these initiatives, enhancing product development and market penetration efforts.

## Funding rounds

- Series A, Feb 19, 2019, $6M — OTV
- Seed, Aug 14, 2017 — PLUS Ventures, Mindset Ventures, My Seed Tech Fund

## Investors

- PLUS Ventures — Seed
- Mindset Ventures (https://capitalatlas.ai/funds/mindset-ventures) — Seed
- My Seed Tech Fund (https://capitalatlas.ai/funds/my-seed-tech-fund) — Seed
- OTV (https://capitalatlas.ai/funds/otv) — Series A